All Oncology News

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad, where regulatory permissions are likely to come more slowly than in the United States.

Researchers have determined that CD30-specific CAR T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma.

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved the objective response rate and duration of response compared with sunitinib (Sutent) in patients with treatment-naïve metastatic renal cell carcinoma, according to CheckMate-214.

ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.

Monte Winslow, PhD, shares the work on CRISPR being developed in his lab, and how this technology might help advance treatment for the non-driver NSCLC population.

Thomas Jefferson University Hospital (Sidney Kimmel Cancer Center at Jefferson) is ranked No. 20 in the Nation in the cancer specialty, according to US News and World Report.

Hong Kong researchers were able to detect nasopharyngeal carcinoma significantly earlier by screening for circulating cell-free Epstein-Barr virus DNA.

Jane McElroy, PhD, discusses the association between higher cadmium levels and an increased risk of endometrial cancer.

Kathleen Moore, MD, discusses the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Stacy Loeb, MD, discusses the promise and challenges with genomic testing in prostate cancer.

Robert Siegel, MD, discusses the 13-month follow-up of the combination of induction chemotherapy and transoral surgery in oropharyngeal squamous cell carcinoma.

Jean-Pascal Machiels, MD, discusses the KEYNOTE-412 trial and the overall potential for pembrolizumab in the head and neck cancer landscape.

Maximilian Diehn, MD, PhD, discussed the future of NGS platforms and liquid biopsies and his vision for them eventually becoming standard practice for patients with lung cancer.

Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Andrew Stephenson, MD, discusses the impact of various approaches—radiation, surgery, and active surveillance—on patients’ quality of life 2 years following treatment.

Georgina V. Long, BSc, PhD, MBBS, discusses recent data with the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Millie Das, MD, discusses the difficulties of the non-driver non-small cell lung cancer patient population, interesting clinical trials that could reshape therapeutic options, and her belief that these patients do have molecular targets that have yet to be identified.

Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival outcomes when treated with early docetaxel.

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

Arthur Sung, MD, discusses interventional pulmonary techniques in non-small cell lung cancer.

Tushar Desai, MD, discusses his research in stem cells and why discovering which cells have the potential to form lung cancer is significant to the treatment paradigm.

Adding bevacizumab (Avastin) to chemotherapy improved overall survival for women with cervical cancer, according to final results from the phase III GOG 240 trial.